2014 The pentose phosphate pathway and cancer
The Pentose Phosphate Pathway (PPP) and Its Role in Cancer
Introduction to the Pentose Phosphate Pathway (PPP)
Definition: The PPP branches from glycolysis at the glucose-6-phosphate (G6P) step.
Functionality: Essential for ribonucleotide synthesis and a primary source of NADPH.
Importance: Supplies cancer cells with anabolic building blocks and aids in oxidative stress management due to high rates of metabolism.
Historical Context: The pathway gained attention in the 20th century for its link to hemolytic anemia caused by oxidants affecting glutathione levels.
Structure of the PPP
Branches:
Oxidative Branch: Generates NADPH and ribonucleotides through three irreversible reactions:
G6PDH Activity: Converts G6P into 6-phosphogluconolactone, producing NADPH.
Hydrolysis: 6-phosphogluconolactone is hydrolyzed to form 6-phosphogluconate.
Decarboxylation: 6-phosphogluconate is converted into Ru5P while generating a second NADPH.
Non-Oxidative Branch: Composed of reversible reactions that convert glycolytic intermediates (F6P, G3P) to and from pentose phosphates.
Enzymatic Regulation: Enzymes are allosterically regulated, allowing flexible adaptation to cellular needs, especially in rapidly dividing cells.
The Role of PPP in Cancer Metabolism
Nucleotide Synthesis: Higher demand for nucleotides in fast-dividing cancer cells drives the PPP activity.
NADPH Generation: Essential for various biosynthetic processes, including lipid synthesis and antioxidant defense.
Adaptation under Stress: Cancer cells modulate PPP activity to cope with oxidative stress and the tumor microenvironment.
Regulatory Enzymes in the PPP
G6PDH (Glucose-6-Phosphate Dehydrogenase)
Main Function: First committed step in the oxidative branch producing NADPH.
Regulation: Activity influenced by the NADP+/NADPH ratio; high NADPH levels inhibit G6PDH.
Expression: Overexpressed in many tumor types and regulated by growth factors via post-translational modifications.
6-Phosphogluconolactonase (6PGL)
Function: Catalyzes the hydrolysis of 6-phosphogluconolactone.
Implications in Disease: Mutation linked to hemolytic anemia.
6-Phosphogluconate Dehydrogenase (6PGDH)
Role in Cancer: Critical for lung cancer cell proliferation; silencing this enzyme leads to increased ROS and cellular senescence.
Ribulose-5-Phosphate Isomerase (RPI) and Epimerase (RPE)
RPI Function: Converts Ru5P to ribose-5-phosphate (R5P), essential for nucleotide synthesis.
RPE Role: Converts Ru5P to xylulose-5-phosphate (Xu5P), which affects glycolysis.
Transketolase (TKT) and Transaldolase (TALDO)
Functionality in Non-Oxidative Branch: TKT and TALDO facilitate nucleotide synthesis by redirecting glycolytic intermediates.
Role in Cancer: Elevated expression in various cancers promotes ribonucleotide synthesis crucial for cell proliferation.
Oncogenic Regulation of the PPP
Tumor Suppressor p53
Role: Transcription factor that regulates metabolic genes including those in the PPP.
Effects:
Inhibits glucose transporters (GLUT1, GLUT4) increasing glucose availability for the PPP.
Suppresses glycolytic enzymes, enhancing the oxidative PPP.
Oncogenes (e.g., K-Ras)
Activation Effects: Upregulates non-oxidative PPP and increases glucose flux through enhanced HK2 expression, crucial for nucleotide synthesis.
mTORC1 and Nrf2 Pathways
mTORC1: Enhances transcription of G6PDH and upregulates oxidative PPP activity for fatty acid synthesis.
Nrf2: Activated in response to oxidative stress; increases transcription of PPP enzymes aiding NADPH and nucleotide production.
Implications for Cancer Therapy
Therapeutic Target: Targeting PPP may disrupt cancer cell metabolism and reduce oxidative stress resistance.
Challenges: Drug resistance linked to upregulated PPP; targeting the pathway must consider the complex interplay between cancer metabolism and therapeutic response.
Future Directions: Understanding regulatory mechanisms of the PPP could yield new therapeutic strategies in oncology.